EQS-News: Dermapharm Holding SE / Key word(s): Annual ResultsDermapharm Holding SE: Dermapharm Holding SE surpasses one billion in revenue for first time in 2022 and maintains growth trajectory 28.03.2023 / 07:29 CET/CESTThe issuer is solely responsible for the content of this announcement.Dermapharm Holding SE surp.
12.04.2022 Dermapharm Holding SE records best ever year in 2021 - continuous growth in financial year 2022 | Dermapharm Holding SE | News | Nachricht | Mitteilung
DGAP-News: Dermapharm Holding SE / Key word(s): Annual Results
Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures
13.04.2021 / 07:30
Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures
» Revenue and earnings up due to organic growth and successful acquisitions
» Vaccine production to commence in May 2021 at Allergopharma s site in Reinbek
» Consolidated revenue to grow by 24 % - 26 % in 2021
» Consolidated EBITDA to increase by 45 % - 50 % in 2021
» Dividend proposal of EUR 0.88 per share for 2020
Grünwald, 13 April 2021 - Dermapharm Holding SE ( Dermapharm ), a rapidly growing manufacturer of branded pharmaceuticals for selected therapeutic areas in Germany, today published its full Annual Report 2020. Dermapharm confirms its preliminary consolidated figures (IFRS) for financial year 2020. Both consolidated revenue and consolidated earnings continue on their clear growth trajectory. Gro